#USA #New York #Class Action #Inc. #securities lawsuit #Ardelyx

Class Action Alert for Ardelyx, Inc. Shareholders

Ardelyx, Inc. (NASDAQ: ARDX) is currently facing a class action lawsuit, and Levi & Korsinsky, LLP is reaching out to inform shareholders of the impending deadline to participate. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, may be eligible for recovery. The lead plaintiff deadline is set for November 16, 2026, prompting a call to action for affected shareholders.

Background on the Class Action

The lawsuit centers around significant claims made against Ardelyx's top executives, including its CEO and financial officers. They are individually named in this securities class action, which alleges that during the class period, the company misrepresented its financial outlook, projecting combined peak sales of $1.75 billion for their products XPHOZAH and IBSRELA. Allegedly, these projections were made while access barriers from payers were concurrently increasing, which may have misled investors about the company's actual performance.

Stock Performance and Allegations

Notably, ARDX shares plummeted about 18% following an announcement on August 6, 2026, where the company revised its revenue guidance for IBSRELA down and also retracted its long-term revenue forecasts for XPHOZAH. This announcement led to a loss of $0.87 per share, shocking many investors and calling into question the company's earlier communications about its future financial success.

The legal action holds the four key officers—Michael Raab, Justin Renz, Susan Hohenleitner, and Eric Foster—accountable under both Section 10(b) of the Exchange Act and Section 20(a) Control Person Framework. This implies that they might be directly responsible for any misleading information that contributed to investor losses, instead of hiding behind the corporate entity as often occurs.

Key Points of the Allegations:

• - Control of Public Statements: Each named defendant allegedly had control over the company's public disclosures and may have misled investors regarding their revenue expectations.
• - Revenue Projections: The projection of over $1 billion in sales for IBSRELA and $750 million for XPHOZAH is under scrutiny, particularly concerning the pressure from payer-related restrictions that were not disclosed adequately.
• - Certification Responsibilities: There's an implication that during the class period, certifications for accuracy were signed by different CFOs, potentially complicating accountability regarding the accuracy of the company’s financial reports.

Call to Action for Investors

Shareholders who believe they have suffered losses related to ARDX stock trading should gather relevant documentation such as brokerage records showing purchase details and put options. Levi & Korsinsky encourages affected parties to submit their names for a no-cost evaluation of recovery eligibility. Potential class members do not need to take immediate action, yet being proactive is crucial to retain their rights.

Class action suits provide a way for investors to claim their share of damages. The appointment of a lead plaintiff—typically the investor with the largest losses—will oversee the case on behalf of the entire group, ensuring that the interests and rights of all investors are upheld.

Conclusion

As the deadline approaches, it is essential for Ardelyx investors to act swiftly. If you are part of the affected shareholders, contacting Levi & Korsinsky for guidance on how to proceed could be the first step toward recovering your losses. Remember, even if shares have been sold, eligibility for the class action depends on the purchase date, not current ownership status.

For more information on how to participate, interested parties may reach out to Levi & Korsinsky, LLP by contacting Joseph E. Levi, Esq. via phone or email as provided above.

_Contact: Joseph E. Levi, Esq. (212) 363-7500 or [email protected]_